Methacrylic Acid

Methacrylic Acid

SCHEMBL1844179

C=C(C)C(=O)O.C=C(CCCN(C)C)C(=O)O

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 1/20 0.38
KDM4A O75164 12/20 0.37
KDM4C Q9H3R0 12/20 0.37
KDM5A P29375 1/20 0.37
KDM7A Q6ZMT4 1/20 0.37
PHF8 Q9UPP1 1/20 0.37
KDM2A Q9Y2K7 1/20 0.37
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
TBXAS1 P24557 1/20 0.33
KDM4E B2RXH2 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
DNM1 Q05193 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL6238301 0.94 PAOX (0.39) PAOXKDM4AKDM4CKDM5AKDM7A
SCHEMBL22599 0.94 KDM4A (0.40) PAOXKDM4AKDM4CKDM5AKDM7A
SCHEMBL7502000 0.94 KDM4A (0.40) PAOXKDM4AKDM4CKDM5AKDM7A
Methacrylic Acid SCHEMBL6893904 0.92 KDM4A (0.46) PAOXKDM4AKDM4CKDM5AKDM7A
Hydrochloric Acid SCHEMBL966902 0.92 KDM4A (0.43) PAOXKDM4AKDM4CKDM5AKDM7A
Bromide SCHEMBL1061717 0.92 KDM4A (0.39) PAOXKDM4AKDM4CKDM5AKDM7A
Ammonia Solution, Strong SCHEMBL9070327 0.92 KDM4A (0.39) PAOXKDM4AKDM4CKDM5AKDM7A
Bromomethane SCHEMBL3331850 0.90 KDM4A (0.38) PAOXKDM4AKDM4CKDM5AKDM7A
Iodomethane SCHEMBL3333482 0.90 KDM4A (0.38) PAOXKDM4AKDM4CKDM5AKDM7A
SCHEMBL4859244 0.90 KDM4A (0.46) PAOXKDM4AKDM4CKDM5AKDM7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0889940-B1 ELECTROSPRAYABLE RELEASE COATING MINNESOTA MINING & MFG (US) 2000-05-03 EP claimed
EP-0889940-A1 ELECTROSPRAYABLE RELEASE COATING MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-01-13 EP claimed
US-5858545-A COMPRISING AN UNSATURATED MONOMER, A POLYSILOXANE HAVING UNSATURATED END GROUPS AND ONE OR MORE NONVOLATILE CONDUCTIVITY ENHANCER SOLUBLE IN THE MONOMER AND NOT INTERFERING WITH THE COPOLYMERIZATION MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-01-12 US claimed
WO-1997035941-A1 ELECTROSPRAYABLE RELEASE COATING MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-10-02 WO claimed
US-20110256219-A1 Manufacturing Solid Pharmaceutical Dosage Forms With Visible Micro- And Nanostructured Surfaces And Micro- And Nanostructured Pharmaceutical Dosage Form I-PROPERTY HOLDING CORP. (US) 2011-10-20 US disclosed
US-20110256069-A1 Pharmaceutical Moire Pill I-PROPERTY HOLDING CORP. (US) 2011-10-20 US disclosed
US-20110188051-A1 Secure Tracking Of Tablets I-PROPERTY HOLDING CORP (US) 2011-08-04 US disclosed
EP-2320875-A1 SECURE TRACKING OF TABLETS I-Property Holding Corp. (US) 2011-05-18 EP disclosed
EP-0889940-B1 ELECTROSPRAYABLE RELEASE COATING MINNESOTA MINING & MFG (US) 2000-05-03 EP disclosed
EP-0889940-A1 ELECTROSPRAYABLE RELEASE COATING MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-01-13 EP disclosed
US-5858545-A COMPRISING AN UNSATURATED MONOMER, A POLYSILOXANE HAVING UNSATURATED END GROUPS AND ONE OR MORE NONVOLATILE CONDUCTIVITY ENHANCER SOLUBLE IN THE MONOMER AND NOT INTERFERING WITH THE COPOLYMERIZATION MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-01-12 US disclosed
WO-1997035941-A1 ELECTROSPRAYABLE RELEASE COATING MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110256219-A1 Manufacturing Solid Pharmaceutical Dosage Forms With Visible Micro- And Nanostructured Surfaces And Micro- And Nanostructured Pharmaceutical Dosage Form MYH10, MITF, CYP2C19 PAOX 3773/4885KDM4A 4594/4885KDM4C 3866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.